Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Silk Road Medical, Inc (NASDAQ:SILK ) Q1 2024 Results Conference Call April 30, 2024 4:30 PM ET Company Participants Marissa Bych - IR Chas McKhann - Chief Executive Officer Lucas Buchanan - CFO and COO Conference Call Participants Rohin Patel - JPMorgan Rick Wise - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to Silk Road Medical's 2024 First Quarter Earnings Conference Call.

Silk Road Medical, Inc (SILK) Q1 2024 Earnings Call Transcript

SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024.

Silk Road Medical Reports First Quarter 2024 Financial Results

SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference

Silk Road Medical (SILK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Silk Road Medical (SILK) Rating Upgrade to Buy

SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024

Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.

Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio

SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE ® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio. This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the TCAR procedure.

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS

Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Silk Road Medical (SILK) Upgraded to Buy: What Does It Mean for the Stock?

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

SUNNYVALE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States. This launch expands upon the company's prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy. TCAR is a minimally invasive, surgical procedure designed to provide best-in-class stroke protection while minimizing adverse events.

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System

Silk Road Medical, Inc (SILK) Q4 2023 Earnings Call Transcript

Silk Road Medical (SILK) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.34 per share a year ago.

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates

SUNNYVALE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2023.

Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook

SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?

SUNNYVALE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Silk Road Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Silk Road Medical, Inc (NASDAQ:SILK ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Director, Investor Relations Jack Lasersohn - Chairman Chas McKhann - Chief Executive Officer Lucas Buchanan - Chief Financial Officer and COO Conference Call Participants John McAulay - Stifel Rohin Patel - JPMorgan Adam Maeder - Piper Sandler Kristen Stewart - CL King Suraj Khalia - Oppenheimer & Company Michael Polark - Wolfe Research Operator Good day and thank you for standing by. Welcome to the Silk Road Medical Third Quarter 2023 Conference Call.

Silk Road Medical, Inc (SILK) Q3 2023 Earnings Call Transcript

SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2023.

Silk Road Medical Reports Third Quarter 2023 Financial Results

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SILK). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for

SUNNYVALE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Third Quarter 2023 Financial Results on November 8, 2023

Silk Road Medical is a medical device company that focuses on preventing strokes. The company released preliminary third-quarter numbers and reduced yearly revenue guidance.

Why Shares of Silk Road Medical Are Dropping Wednesday

Silk Road Medical (NASDAQ:SILK) stock halved in value at the start of Wednesday's trading after an after-hours profit warning. The company, which has developed a treatment for carotid artery disease, which is a cause of stroke, on Tuesday downgraded revenue guidance and announced the pending retirement of its chief executive Erica Rogers.

Silk Road Medical stock plummets on CEO exit and revenue downgrade

Silk Road Medical (NASDAQ: SILK ) stock is falling hard on Wednesday after the medical device company released preliminary earnings results for Q3 2023. A press release from Silk Road Medical reveals that the company is expecting revenue for the third quarter of the year to come in at about $44.4 million.

Why Is Silk Road Medical (SILK) Stock Down 40% Today?

Two pieces of news are weighing on shares of the medical devices company.

News for Silk Road Medical Inc Stock (SILK)